AKYA vs. ALNT, EYPT, AEHR, QTRX, QSI, NAUT, KEQU, FEIM, RPID, and SEER
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Allient (ALNT), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Quanterix (QTRX), Quantum-Si (QSI), Nautilus Biotechnology (NAUT), Kewaunee Scientific (KEQU), Frequency Electronics (FEIM), Rapid Micro Biosystems (RPID), and Seer (SEER). These companies are all part of the "measuring and control equipment" industry.
Akoya Biosciences vs.
Allient (NASDAQ:ALNT) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk.
In the previous week, Allient had 1 more articles in the media than Akoya Biosciences. MarketBeat recorded 5 mentions for Allient and 4 mentions for Akoya Biosciences. Allient's average media sentiment score of 1.18 beat Akoya Biosciences' score of 1.06 indicating that Allient is being referred to more favorably in the media.
Allient has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.
61.6% of Allient shares are held by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are held by institutional investors. 15.6% of Allient shares are held by insiders. Comparatively, 7.3% of Akoya Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Akoya Biosciences received 28 more outperform votes than Allient when rated by MarketBeat users. However, 75.00% of users gave Allient an outperform vote while only 59.65% of users gave Akoya Biosciences an outperform vote.
Allient has higher revenue and earnings than Akoya Biosciences. Akoya Biosciences is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.
Allient has a net margin of 2.64% compared to Akoya Biosciences' net margin of -66.77%. Allient's return on equity of 10.80% beat Akoya Biosciences' return on equity.
Allient presently has a consensus price target of $31.00, suggesting a potential upside of 16.22%. Akoya Biosciences has a consensus price target of $5.43, suggesting a potential upside of 164.16%. Given Akoya Biosciences' higher possible upside, analysts plainly believe Akoya Biosciences is more favorable than Allient.
Summary
Allient beats Akoya Biosciences on 15 of the 19 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:AKYA) was last updated on 2/22/2025 by MarketBeat.com Staff
